"I'm a good mother; I play with her; I love her": The motherhood experience of women with intellectual disabilities from empowering and intersectional approaches

被引:2
|
作者
Shpigelman, Carmit-Noa [1 ,3 ]
Bar, Moran [2 ]
机构
[1] Univ Haifa, Dept Community Mental Hlth, Haifa, Israel
[2] Univ Haifa, Sch Social Work, Haifa, Israel
[3] Univ Haifa, Fac Social Welf & Hlth Sci, Dept Community Mental Hlth, 199 Aba Khoushy Ave, IL-3498838 Hefa, Israel
关键词
Motherhood; Intellectual disability; Intersectionality; Identity; Well-being; PREGNANCY; PEOPLE;
D O I
10.1016/j.dhjo.2023.101504
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Despite the growing recognition of the right of women with disabilities to become mothers, this right remains significantly under-fulfilled among women with intellectual disabilities (ID). Whereas the voice of mothers with ID has begun being heard in research, most studies still focus on the barriers to motherhood and the difficulties associated with childrearing.Objective: The study aims to understand and describe the subjective experiences of mothers with ID, focusing on positive aspects from empowering and intersectional approaches.Method: Semi-structured interviews were conducted with 11 mothers with ID who live in the com-munity and raise their children.Results: Four themes emerged from the interviews: (1) A dream that came through; (2) Motherhood as an empowering process; (3) The intersection between the disability identity and the motherhood identity; (4) Family involvement as a resource and a challenge. Conclusions: The findings highlight the need to meet the mothers' twofold identity in an empowering way by constructing a more positive disability identity and further cultivating their motherhood identity. They also highlight the important role of the family in supporting mothers with ID. A positive disability identity and family support are needed to increase these women's emotional well-being and overall quality of life.(c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 40 条
  • [31] I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ER+, HER2-breast cancer and molecular good-prognosis gene signature.
    Haddad, Tufia C.
    Shah, Mamta D.
    Symmans, William Fraser
    Hylton, Nola
    Yau, Christina
    Lyandres, Julia
    Melisko, Michelle E.
    Forero, Andres
    Albain, Kathy S.
    Kaplan, Henry G.
    Viscusi, Rebecca Klein
    Berry, Donald A.
    Esserman, Laura
    Chien, Amy Jo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+breast cancer"
    Cao, Lifen
    Stabellini, Nickolas
    Amin, Amanda L.
    Montero, Alberto J.
    CANCER, 2022, 128 (16) : 3130 - 3130
  • [33] Silent Tears of Midwives: 'I Want Every Mother Who Gives Birth to Have Her Baby Alive'-A Narrative Inquiry of Midwives Experiences of Very Early Neonatal Death from Tanzania
    Becker, Jan
    Becker, Chase
    Abeysekera, Rachel
    Moir, James
    Gray, Marion
    Shimwela, Meshack
    Oprescu, Florin
    CHILDREN-BASEL, 2023, 10 (04):
  • [34] Request from Rita de Sousa Lobo, a resident of Ouro Preto, a former slave, asks D. Maria I to order her daughters to be free as daughters, who were liberated mother
    Merce, E. Rogo
    REVISTA BRASILEIRA DE HISTORIA & CIENCIAS SOCIAIS, 2009, 1 (02):
  • [35] "I got courage from knowing that even a daughter-in-law can earn her living": Mixed methods evaluation of a family-centred intervention to prevent violence against women and girls in Nepal
    Shai, Nwabisa
    Pradhan, Geeta Devi
    Shrestha, Ratna
    Adhikari, Abhina
    Chirwa, Esnat
    Kerr-Wilson, Alice
    Jewkes, Rachel
    PLOS ONE, 2020, 15 (05):
  • [37] Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
    Bellon, Jennifer R.
    Tayob, Nabihah
    Yang, David D.
    Tralins, Jordan
    Dang, Chau T.
    Isakoff, Steven J.
    DeMeo, Michelle
    Burstein, Harold J.
    Partridge, Ann H.
    Winer, Eric P.
    Krop, Ian E.
    Tolaney, Sara M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (01): : 117 - 124
  • [38] Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer
    Bellon, J. R.
    Tayob, N.
    Burstein, H. J.
    Partridge, A.
    Demeo, M. K.
    Tralins, J.
    Yang, D. D.
    Dang, C.
    Isakoff, S. J.
    Yardley, D.
    Valero, V.
    Winer, E.
    Krop, I.
    Tolaney, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S34 - S34
  • [39] SERENA-1: Results from a Phase 1 study (Parts I/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer
    Vaklavas, Christos
    Oliveira, Mafalda
    Armstrong, Anne
    Moreno, Irene
    Twelves, Chris
    Ruiz, Ivan Victoria
    Bermejo, Begona
    Ajimi, Maxine
    Brier, Tim
    Ciardullo, Carmela
    Gibbons, Lisa
    Irurzun-Arana, Itziar
    Jack, Tony
    Klinowska, Teresa
    Lindemann, Justin
    Mathewson, Alastair
    Morrow, Christopher
    Sykes, Andy
    Baird, Richard
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Liu, Funan
    Gong, Jifang
    Jin, Zhaoyu
    Zhang, Miao
    Zhang, Shu
    Zhang, Yanqiao
    Liang, Xinjun
    Li, Yun
    Yang, Xiaochun
    Yang, Yaping
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)